Arjeff:
sounds interesting. Do you have a source for that? Obviously I'm an optimist, but it's always good to read a contrary opinion.
I would point out the obvious, namely that they are in the middle of a trial, so technically there is no medically published human data to date on 2566. Apart from the Phase I results of course. And the fact that as far as we know they've had 36 enrolments in Phase II apparently without adverse consequences, certainly without consequences that would warrants changing or stopping the trial and reporting to market.
Arjeff:sounds interesting. Do you have a source for that?...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |